Table 1.
Patient Demographics
| PBSC/BM | UCB | p value | |
|---|---|---|---|
| n=15 | n=15 | ||
| Sex | 0.69 | ||
| Male | 10(66.7%) | 11(73.3%) | |
| Age | 0.25 | ||
| Median(Min-Max) | 63.2(23.4-72.8) | 56.7(44.8-69.5) | |
| Diagnosis | 0.35 | ||
| ALL | 1(6.7%) | 2(13.3%) | |
| AML | 5(33.3%) | 7(46.7%) | |
| Other Leukemia | 0 | 1(6.7%) | |
| Myelodysplasia | 2(13.3%) | 3(20.0%) | |
| Non-Hodgkin's | 4(26.7%) | 2(13.3%) | |
| Lymphoma | |||
| Hodgkin's Lymphoma | 3(20.0%) | 0 | |
| Conditioning | 1.00 | ||
| RIC | 15(100.0%) | 15(100.0%) | |
| ATG in Conditioning | 1.00 | ||
| Yes | 3(20.0%) | 3(20.0%) | |
| GVHD prophylaxis | 1.00 | ||
| CSA +/− MMF +/− MTX | 13(86.7%) | 13(86.7%) | |
| Siro +/− Tacro +/−MMF | 2(13.3%) | 2(13.3%) | |
| aGVHD II-IV | 0.23 | ||
| Yes | 3(20.0%) | 6(40.0%) | |
| No | 12(80.0%) | 9(60.0%) | |
| Time to aGVHD II-IV | 0.79 | ||
| Median days (Min-Max) | 37.0(30.0-38.0) | 39.0(21.0-115.0) | |
| D+100 Donor Engraftment in CD3+ Fraction | 0.14 | ||
| n | 15 | 11 | |
| Median (Min-Max) | 99.0 (56.0-100.0) | 100.0 (75.0-100.0) | |